[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUS1500047I1 - Rekombináns vakcina West Nile vírus ellen - Google Patents

Rekombináns vakcina West Nile vírus ellen

Info

Publication number
HUS1500047I1
HUS1500047I1 HUS1500047C HUS1500047C HUS1500047I1 HU S1500047 I1 HUS1500047 I1 HU S1500047I1 HU S1500047 C HUS1500047 C HU S1500047C HU S1500047 C HUS1500047 C HU S1500047C HU S1500047 I1 HUS1500047 I1 HU S1500047I1
Authority
HU
Hungary
Prior art keywords
fever virus
vaccine against
nile fever
nile
vaccine
Prior art date
Application number
HUS1500047C
Other languages
English (en)
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of HUS1500047I1 publication Critical patent/HUS1500047I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUS1500047C 2001-04-06 2015-09-18 Rekombináns vakcina West Nile vírus ellen HUS1500047I1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil

Publications (1)

Publication Number Publication Date
HUS1500047I1 true HUS1500047I1 (hu) 2017-03-28

Family

ID=8862055

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0401868A HU230122B1 (hu) 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen
HUS1500047C HUS1500047I1 (hu) 2001-04-06 2015-09-18 Rekombináns vakcina West Nile vírus ellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0401868A HU230122B1 (hu) 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen

Country Status (22)

Country Link
EP (2) EP1377660B1 (hu)
JP (1) JP4426761B2 (hu)
AU (1) AU2002307971B2 (hu)
BE (1) BE2016C021I2 (hu)
BR (1) BRPI0208896B1 (hu)
CA (1) CA2448796C (hu)
CY (2) CY1117676T1 (hu)
DK (1) DK1377660T3 (hu)
ES (2) ES2767413T3 (hu)
FR (2) FR2823222B1 (hu)
HK (2) HK1219412A1 (hu)
HU (2) HU230122B1 (hu)
IL (3) IL158204A0 (hu)
LT (1) LTC1377660I2 (hu)
LU (1) LU93048I2 (hu)
MX (1) MXPA03008998A (hu)
NL (1) NL300806I2 (hu)
PL (2) PL207584B1 (hu)
RU (1) RU2283138C2 (hu)
SI (1) SI1377660T1 (hu)
WO (1) WO2002081621A2 (hu)
ZA (1) ZA200307620B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521867A (ja) 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
CA2452545C (en) 2001-07-27 2015-06-09 Wyeth West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus
JP2006509526A (ja) * 2002-12-13 2006-03-23 アヴェンティス パストゥール インコーポレイテッド トリ胚性幹細胞上におけるａｌｖａｃの産生
EP1626708B1 (en) 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
KR101492643B1 (ko) 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
JP5713454B2 (ja) 2008-08-29 2015-05-07 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ウエストナイルウイルスワクチン
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
CA3017298C (en) * 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
RU2209082C2 (ru) * 1997-02-28 2003-07-27 Оравакс, Инк. Химерные флавивирусные вакцины
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
CZ20014392A3 (cs) 1999-06-10 2002-06-12 Merial Vakcína AND pro domácí a sportovní zvířata
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
HUP0401868A2 (hu) 2004-12-28
ES2767413T3 (es) 2020-06-17
IL158204A (en) 2013-03-24
AU2002307971B2 (en) 2008-01-17
CY2016018I2 (el) 2016-12-14
EP2979705B1 (fr) 2019-10-23
DK1377660T3 (en) 2016-03-29
HK1061868A1 (zh) 2004-10-08
MXPA03008998A (es) 2004-10-15
BE2016C021I2 (hu) 2021-03-23
FR2823222B1 (fr) 2004-02-06
NL300806I2 (hu) 2016-06-09
HK1219412A1 (zh) 2017-04-07
JP2004531521A (ja) 2004-10-14
SI1377660T1 (sl) 2016-05-31
ES2566044T3 (es) 2016-04-08
BR0208896A (pt) 2004-07-20
RU2283138C2 (ru) 2006-09-10
PL207584B1 (pl) 2011-01-31
IL158204A0 (en) 2004-05-12
HU230122B1 (hu) 2015-08-28
CA2448796A1 (en) 2002-10-17
WO2002081621A3 (fr) 2003-02-20
WO2002081621A2 (fr) 2002-10-17
IL185263A0 (en) 2008-01-06
PL210306B1 (pl) 2011-12-30
PL365210A1 (en) 2004-12-27
EP1377660B1 (fr) 2016-01-13
FR2823222A1 (fr) 2002-10-11
CA2448796C (en) 2012-11-20
JP4426761B2 (ja) 2010-03-03
EP2979705A1 (fr) 2016-02-03
RU2003132455A (ru) 2005-04-27
FR16C0014I1 (hu) 2016-05-27
EP1377660A2 (fr) 2004-01-07
HUP0401868A3 (en) 2011-06-28
ZA200307620B (en) 2005-07-27
FR16C0014I2 (fr) 2016-09-09
CY1117676T1 (el) 2016-12-14
BRPI0208896B1 (pt) 2016-06-07
CY2016018I1 (el) 2016-12-14
LU93048I2 (fr) 2016-06-27
LTC1377660I2 (lt) 2017-04-25

Similar Documents

Publication Publication Date Title
HUS1500047I1 (hu) Rekombináns vakcina West Nile vírus ellen
IL158066A0 (en) Vaccine composition
HK1067891A1 (en) Influenza vaccine composition
EP1427444A4 (en) WEST NILE VACCINE
HUP0402471A3 (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0407935D0 (en) Vaccine
DK1265633T3 (da) Vaccineadjuvans
HUP0303372A3 (en) Vaccine
EP1423141A4 (en) VACCINE
GB0306611D0 (en) Novel vaccine
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
GB0121171D0 (en) Vaccine
AU2002307971A1 (en) Vaccine against the nile fever virus
EP1395262A4 (en) NUCLEOSIDE-VACCINE-ADJUVANTS
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
GB0105238D0 (en) Vaccines
GB0113552D0 (en) Vaccines
GB0115496D0 (en) Vaccine
GB0103867D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0130823D0 (en) Vaccine
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
PL374051A1 (en) Salmonella vaccine
GB0100430D0 (en) Virus strains